A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients.

Trial Profile

A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2013

At a glance

  • Drugs IC 43 (Primary) ; Aluminium hydroxide
  • Indications Pseudomonal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Valneva
  • Most Recent Events

    • 26 Oct 2010 Primary endpoint 'Immunoglobulin G levels' has been met. IgG antibody Geometric Mean Titers were 995-2117ELISA units/mL.
    • 26 Oct 2010 Results reported in a Intercell media release.
    • 02 Jun 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top